aTyr Pharma, Inc.

For 2024, collaboration and license revenue tied to the Kyorin agreement was $0.2 million. Research and development expense was $54.4 million and general and administrative expense was $13.8 million for the year ended 2024. The company ended 2024 with $75.1 million in cash, restricted cash, cash equivalents, and investments, and raised approximately $18.8 million in gross proceeds after quarter-end from its ATM program. Management said cash runway is expected to fund operations through 1-year following the Phase 3 EFZO-FIT readout, and some ATM proceeds will be used for commercial readiness. No quarterly revenue or EPS was reported on the call. Forward-looking timing includes EFZO-FIT top-line data in the third quarter and interim EFZO-CONNECT skin data in the second quarter.

Sanjay Shukla framed 2024 as a pivotal year because the company completed enrollment in what he called the largest interventional pulmonary sarcoidosis study ever conducted. He emphasized that the FDA-aligned endpoint clarification simplifies the analysis without changing the study’s over-90% power, and he repeatedly returned to confidence in efzofitimod’s safety, durability, and commercial potential. His tone was highly upbeat, with strong emphasis on regulatory discipline, market opportunity, and the possibility of a transformative sarcoidosis outcome later this year.

Jill Broadfoot focused on liquidity, spend, and runway. She said year-end cash, restricted cash, cash equivalents, and investments totaled $75.1 million, and the company raised about $18.8 million in gross proceeds via the ATM after quarter-end. She cited full-year 2024 R&D of $54.4 million and G&A of $13.8 million, and said the updated runway guidance now covers operations through one year after the Phase 3 EFZO-FIT readout, with some ATM proceeds earmarked for commercial readiness and launch preparation.

Analyst questions concentrated on the FDA-driven statistical plan change, the expanded access program, and whether the new endpoint could affect trial interpretation. Management said the change was mainly about simplification and pre-specification, with no change to the study’s power, and noted that a trailing 28-day view helps handle patients who are still tapering near week 48. On the EAP, management would not estimate a participation percentage, saying uptake is site- and country-dependent, but described interest as robust and emphasized that patients and investigators remain blinded to treatment assignment. Questions also probed the Phase 2 steroid reduction data, FEV1’s role, and the scleroderma interim readout; management said FEV1 was discussed little with the FDA and that the upcoming scleroderma skin data are mainly meant to learn about biology, not to read through directly to sarcoidosis.